Intellia Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
State Street Corporation has disclosed beneficial ownership of 6.8% of Intellia Therapeutics' common stock as of June 30, 2026.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5.03% of Intellia Therapeutics Inc.'s common stock as of March 31, 2026.
NASDAQ
Vanguard Portfolio Management has reported a beneficial ownership of 5.3% of Intellia Therapeutics Inc.'s common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G for Intellia Therapeutics Inc., reporting 0% beneficial ownership following an internal realignment.
NASDAQ
The Goldman Sachs Group and its subsidiary report a 2.7% passive beneficial ownership in Intellia Therapeutics, Inc. as of December 31, 2025.
NASDAQ
Contrarius Investment Management entities have reported a 0.6% beneficial ownership stake in Intellia Therapeutics, Inc. as of December 31, 2025.
NASDAQ
State Street Corporation has reported a 5.5% beneficial ownership stake in Intellia Therapeutics Inc., holding over 6.4 million common shares.
NASDAQ
ARK Investment Management LLC and Catherine D. Wood have jointly filed an Amendment No. 8 on Schedule 13G, reporting a combined beneficial ownership of 12.27% in Intellia Therapeutics, Inc.
NASDAQ
The Vanguard Group updated its beneficial ownership in Intellia Therapeutics Inc., reporting an 11.23% stake as of December 31, 2025.
NASDAQ
Goldman Sachs Group and its subsidiary, Goldman Sachs & Co. LLC, reported beneficial ownership of 5.1% of Intellia Therapeutics, Inc.'s common stock as of September 30, 2025.
NASDAQ
Contrarius Investment Management entities have reported a combined beneficial ownership of 5.5% of Intellia Therapeutics, Inc.'s common stock.
NASDAQ
ARK Investment Management LLC and Catherine D. Wood have filed an Amendment No. 7 on Schedule 13G, reporting a combined beneficial ownership of 11.10% in Intellia Therapeutics, Inc.
NASDAQ
State Street Corporation has reported a passive beneficial ownership of 4.4% in Intellia Therapeutics Inc., holding 4,510,261 shares of common stock as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 8.2% Passive Stake in Intellia Therapeutics
BlackRock, Inc. has filed an updated Schedule 13G, revealing a passive beneficial ownership of 8.2% of Intellia Therapeutics, Inc.'s common stock as of March 31, 2025.
NASDAQ
The Vanguard Group has reported a 10% beneficial ownership stake in Intellia Therapeutics Inc., holding over 10 million shares as a passive investor.